Publication:
Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine.

Loading...
Thumbnail Image

Date

2020-11-06

Authors

Tejada Cifuentes, Francisco
Lloret Callejo, Ángeles
Tirado Peláez, María José
Rubio Pulido, Olga
Ruiz-Morote Aragón, Marta
Fernández Urrusuno, Rocío
Muñoz Carreras, María Isabel
Méndez Esteban, María Isabel
Maestre Sánchez, Victoria
García Bonilla, Antonio

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

To analyze the incidence of Covid-19 in patients who are chronic users of hydroxychloroquine. Cross-sectional retrospective observational multicenter study in health areas and districts from Castilla La-Mancha and Andalucia. Of the 4451 participants included in the first recruitment, 3817 with valid data were selected. The main variable of the study is the presence or absence of Covid-19 infection by clinical, serological or polymerase chain reaction diagnosis. Sociodemographic and clinical variables and treatment and concomitant comorbidities were recorded. 169 (4,45%) patients had Covid-19 infection, of which 12 (7.1%) died and 32 (18.9%) required hospital admission. Previous respiratory pathology was related to Covid-19 infection (P There is no relationship between chronic use of hydroxychloroquine and the incidence of Covid-19.

Description

MeSH Terms

Adult
Aged
Aged, 80 and over
Antirheumatic Agents
Arthritis, Rheumatoid
COVID-19
COVID-19 Testing
Chronic Disease
Cross-Sectional Studies
Female
Humans
Hydroxychloroquine
Incidence
Lupus Erythematosus, Systemic
Male
Middle Aged
Prognosis
Protective Factors
Retrospective Studies
Risk Factors
Spain

DeCS Terms

CIE Terms

Keywords

COVID-19, Coronavirus, Hidroxicloroquina, Hydroxychloroquine, Incidence, Incidencia, Tratamiento, Treatment

Citation